Interventional Glaucoma

George Waring IV, MD serves as guest host for ‘History and Evolution of Contemporary Refractive Surgery’

Artificial intelligence and genetic testing are expected to facilitate choosing the best treatment for each unique glaucoma patient within the next decade. This will not only lead to the best outcomes for individuals but will also spare them the costs and side effects of suboptimal treatments.

Ophthalmologists share the most pressing issues on their mind within the glaucoma space — and why losing sleep from time to time may actually be a good thing.

A clinical trial of NCX 470 will evaluate the drug for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

Evidence for a connection between low vitamin D levels and glaucoma is increasing but the link remains speculative and no causal connection has been demonstrated.

A supraciliary minimally invasive glaucoma procedure may offer a valuable bleb-free treatment option for patients with glaucoma that requires low target pressures.

Physician presents pearls for effective use, leading to positive outcomes for patients.

Intraocular drainage surgery in angle closure remains experimental and investigators are collecting data regarding its efficacy as well as adverse effects.

In this latest EyePod® episode, Sahar Bedrood, MD, PhD, shares her clinical perspective on the multi-faceted, dynamic evolution of interventional glaucoma.

Patients show impressive proptosis and diplopia responses to teprotumumab.

Dr Anthony Khawaja, speaks on how ophthalmologists can revolutionise the diagnosis and treatment of glaucoma through precision management.

Arsham Sheybani, MD, offers insight on how his glaucoma patient management protocols have altered and the shift in subconjunctival surgery in light of the pandemic.

New World Medical relied on feedback from surgeons in the development of the device, which was registered with the FDA in October.

Kuldev Singh, MD, MPH, professor/director of the Glaucoma Service Stanford Medical Center, shares the highlights from his discussion on surgical procedure decision-making in the era of MIGS.

Shan C. Lin, MD, co-research director, Glaucoma Center of San Francisco, speaks on the highlights from his presentation on the latest in the three forms of cyclophotocoagulation commonly used by clinicians.

J. Michael Jumper, MD, a retinal specialist at West Coast Retina (San Francisco, CA), discusses the highlights of his Glaucoma 360 presentation analyzing the impact and lasting effects of intraocular injections and retinal diseases in creating glaucoma as well as the evolving collaboration between retinal and glaucoma specialists.

L. Jay Katz, MD, of the Wills Eye Hospital, Philadelphia, PA, discusses the highlights of his Glaucoma 360 presentation on secondary glaucoma due to intravitreal steroids, and what ophthalmologists can do to minimize the risk of severe visual impairment in patients.

Drops can simplify dosing, improving adherence and ocular surface health

Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.

Intraocular drainage surgery may have a future for treating issues.

Consider ideas about outflow pathways, neuroprotection.

Once-daily corticosteroid treats pain, inflammation after surgery.

Results of a survey among ophthalmologists indicate that patients are receiving fewer examinations — with worsening glaucoma, says S. Fabian Lerner, MD, speaking at the Glaucoma 360 New Horizons Forum.

A new therapy provides noninvasive nighttime IOP control by programming the desired pressure into the device, explained John Berdahl, MD, during the New Horizons Forum.

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.